Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1038/NRNEUROL.2017.99 | ||||
| Año | 2017 | ||||
| Tipo | revisión |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
The clinical manifestation of neurodegenerative diseases is initiated by the selective alteration in the functionality of distinct neuronal populations. The pathology of many neurodegenerative diseases includes accumulation of misfolded proteins in the brain. In physiological conditions, the proteostasis network maintains normal protein folding, trafficking and degradation; alterations in this network - particularly disturbances to the function of endoplasmic reticulum (ER) - are thought to contribute to abnormal protein aggregation. ER stress triggers a signalling reaction known as the unfolded protein response (UPR), which induces adaptive programmes that improve protein folding and promote quality control mechanisms and degradative pathways or can activate apoptosis when damage is irreversible. In this Review, we discuss the latest advances in defining the functional contribution of ER stress to brain diseases, including novel evidence that relates the UPR to synaptic function, which has implications for cognition and memory. A complex concept is emerging wherein the consequences of ER stress can differ drastically depending on the disease context and the UPR signalling pathway that is altered. Strategies to target specific components of the UPR using small molecules and gene therapy are in development, and promise interesting avenues for future interventions to delay or stop neurodegeneration.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | HETZ-FLORES, CLAUDIO ANDRES | Hombre |
Universidad de Chile - Chile
Centro de Gerociencia, Salud Mental y Metabolismo - Chile |
| 2 | Saxena, Smita | Mujer |
Univ Bern - Suiza
UniversitätsSpital Bern - Suiza University Hospital Bern - Suiza |
| Fuente |
|---|
| FONDECYT |
| Fondef |
| FONDAP |
| Fondo Nacional de Desarrollo Científico y Tecnológico |
| Fondo de Fomento al Desarrollo Científico y Tecnológico |
| Millennium Institute |
| Air Force Office of Scientific Research |
| European Research Council |
| Muscular Dystrophy Association |
| Swiss National Science Foundation |
| Fondo Nacional de Desarrollo CientÃfico y Tecnológico |
| Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung |
| ALSRP Therapeutic Idea Award |
| Fondo de Fomento al Desarrollo CientÃfico y Tecnológico |
| US Air Force Office of Scientific Research |
| US Office of Naval Research-Global (ONR-G) |
| Michael J. Fox Foundation for Parkinson's Research |
| CONICYT-Brazil |
| US Office of Naval Research-Global |
| ALS Therapy Alliance |
| Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung |
| Frick Foundation |
| Synapsis Foundation |
| Michael J Fox Foundation for Parkinson's Research - Target Validation |
| Frick foundation for ALS research |
| Stiftung UNISCIENTIA |
| Michael J Fox Foundation |
| Uniscientia Stiftung |
| Agradecimiento |
|---|
| C.H. is supported by the FONDAP program 15150012, the US Office of Naval Research-Global (ONR-G) N62909-16-1-2003, the Millennium Institute P09-015-F, FONDEF ID16I10223, FONDEF D11E1007, the US Air Force Office of Scientific Research FA9550-16-1-0384, CONICYT-Brazil 441921/2016-7, the ALS Therapy Alliance 2014-F-059, the Muscular Dystrophy Association 382453, the Michael J Fox Foundation for Parkinson's Research - Target Validation grant No 9277, FONDECYT no. 1140549, and the ALSRP Therapeutic Idea Award AL150111. S.S. is supported by the Synapsis Foundation, Stiftung UNISCIENTIA, the Frick foundation for ALS research, Swiss National Science Foundation and European Research Council 725825. |
| C.H. is supported by the FONDAP program 15150012, the US Office of Naval Research-Global (ONR.G) N62909- 16.1.2003, the Millennium Institute P09.015.F, FONDEF ID16I10223, FONDEF D11E1007, the US Air Force Office of Scientific Research FA9550-16.1.0384, CONICYT-Brazil 441921/2016.7, the ALS Therapy Alliance 2014.F-059, the Muscular Dystrophy Association 382453, the Michael J Fox Foundation for Parkinson's Research . Target Validation grant No 9277, FONDECYT no. 1140549, and the ALSRP Therapeutic Idea Award AL150111. S.S. is supported by the Synapsis Foundation, Stiftung UNISCIENTIA, the Frick foundation for ALS research, Swiss National Science Foundation and European Research Council 725825. |